Navigation Links
Breast Cancer Study Offers New Hope
Date:5/25/2010

Estrogen-lowering drugs before surgery let even high-risk women opt for lumpectomy

TUESDAY, May 25 (HealthDay News) --Giving certain breast cancer patients estrogen-lowering drugs before surgery enhances their chances of being able to choose a breast-conserving lumpectomy instead of a full mastectomy, new research suggests.

The observation was based on a national study launched at 118 hospitals across the United States. It focused on postmenopausal women who had been diagnosed with estrogen receptor-positive (ER+) breast cancer that was either at stage II or stage III -- that is, tumors that were around an inch or greater in size and might have spread to the lymph nodes under the arm.

The most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.

The 352 women who participated were monitored for tumor growth before and after being placed on a 16-week regimen of aromatase inhibitors -- estrogen-lowering agents -- before any surgery. Estrogen stimulates the growth of ER+ tumors.

The women were classified into three groups as the study began: "marginal", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; "mastectomy-only", meaning a lumpectomy was not considered possible; and "inoperable", meaning that doctors believed that even a mastectomy would not completely remove the cancer.

After the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.

More than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome. And 75 percent of those thought to be inoperable altogether were able to have breast-conservation surgery.

The investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.

"Aromatase inhibitor therapy shrank the tumors in many of these women and improved surgical outcomes," study chair Dr. Matthey J. Ellis, a breast cancer specialist at Washington University and Barnes-Jewish Hospital, said in a news release. "These results will encourage a change in practice across the country so that more women can benefit from the currently underutilized approach of administering estrogen-lowering agents before surgery."

The findings are scheduled to be presented June 7 at the American Society of Clinical Oncology annual meeting, in Chicago.

More information

For more on surgical options for breast cancer, visit the U.S. National Cancer Institute.



--Alan Mozes



SOURCE: American Society of Clinical Oncology meeting, May 20, 2010, news release.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted therapy prolongs life in patients with HER2-positive breast cancer
2. New Drugs, New Combinations Fight Breast Cancer
3. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
4. Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites
5. Prolactin blocks oncogene associated with poor prognosis in breast cancer
6. Definitive study confirms chemo benefit in postmenopausal breast cancer
7. Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients
8. Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer
9. Bone Drugs May Beat Back Breast Cancer
10. California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts
11. Alcohol consumption may increase breast cancer recurrence risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), ... latest Artificial Intelligence (AI) thinking, announced today the launch of its revamped web ... essential information that offers a more comprehensive understanding of the organization’s business and ...
(Date:9/20/2017)... ... September 20, 2017 , ... On Thursday, the Triangle ... Work in the Research Triangle for 2017. , Winners were chosen based on ... meet a threshold in employee participation--a percentage that varies based upon the size ...
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added ... network of medical professionals working on a personal injury lien basis. Founded by Dr. ... brings these esteemed doctors’ vast experience with orthopedic injuries to patients in the Inland ...
(Date:9/20/2017)... ... 2017 , ... Mirror Mirror Beauty Boutique is excited to ... Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include live ... Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that ... clinical and commercial support services market) has entered into an agreement on September ... , The PGSD is the first private Dental School to launch an ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
Breaking Medicine Technology: